Physician profile
Michael Christopher Large
NPI 1346489630
$24,566.74
in general payments reported to CMS, 2019-2025
51 companies · $5,570 in 2025
The $5,570 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $2,309 · 2021: $3,002 · 2022: $882 · 2023: $6,572 · 2024: $4,324 · 2025: $5,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,286 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,032.06 |
| Food and Beverage | $4,285.78 |
| Education | $147.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $5,967.49 | 2019-2025 | Adstiladrin |
| Janssen Biotech, INC. | $5,542.46 | 2019-2025 | Erleada, Akeega, Balversa |
| Astrazeneca Pharmaceuticals LP | $4,432.43 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,077.60 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $900.78 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $664.48 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $603.06 | 2019-2025 | Xtandi, Padcev, Veozah |
| Pfizer INC. | $494.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $466.74 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Sumitomo Pharma America, INC. | $261.26 | 2023-2025 | Orgovyx, Gemtesa |
| Histosonics, INC. | $258.07 | 2025 | |
| Novartis Pharmaceuticals Corporation | $214.91 | 2019-2025 | |
| Urogen Pharma, INC. | $213.91 | 2021-2025 | Jelmyto |
| Genzyme Corporation | $212.72 | 2019-2023 | |
| Immunitybio, INC. | $186.32 | 2024-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Large listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.